Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis
Aliment Pharmacol Ther
.
2016 Aug;44(3):310-1.
doi: 10.1111/apt.13692.
Authors
S Renna
1
,
E Orlando
1
,
F S Macaluso
1
,
M Maida
2
,
M Affronti
1
,
M Giunta
2
,
C Sapienza
1
,
G Rizzuto
1
,
R Orlando
1
,
M Dimarco
1
,
M Cottone
1
,
A Orlando
3
Affiliations
1
DiBiMis, Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo University, Palermo, Italy.
2
Gastroenterology and Endoscopy Unit, "Villa Sofia-Cervello" Hospital, Palermo, Italy.
3
DiBiMis, Division of Internal Medicine, "Villa Sofia-Cervello" Hospital, Palermo University, Palermo, Italy.
[email protected]
.
PMID:
27375103
DOI:
10.1111/apt.13692
No abstract available
Publication types
Letter
Kommentar
MeSH terms
Adalimumab*
Antibodies, Monoclonal
Colitis, Ulcerative*
Humans
Prospective Studies
Substances
Antibodies, Monoclonal
golimumab
Adalimumab